Keywords: alza, corp, revenues, pushing, billion, rose, million
Alza Corp revenues pushing $1 billion
Article | 01 February 2001
Alza Corp's 2000 revenues rose 24% to $988 million, while net incomejumped 42% to $188 million, driven by sales of Ditropan XL (controlled-release oxybutynin), Doxil/ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
